Ionis Pharmaceutical (NASDAQ:IONS):
Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen.
The company is down by 0.02% percent from yesterday’s close.
Ionis Pharmaceuticals, Inc., launched on March 25, 1991, is involved in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Business’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is involved in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Business’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders..
The P/E ratio is currently 375.97 and the market value is 6.67B. As of the last earnings report the EPS was $0.14 with 124.80M shares presently outstanding.
Short traders are more bearish on the company lately if you put credence in the change in short interest. The firm realized a rise in short interest from September 29, 2017 to October 13, 2017 of 1.88%. Short interest increased 183,369 over that timeframe. The short-interest ratio increased to 10.0 and the short interest percentage is 0.08% as of October 13.
Brokerage firms have released ratings on the company recently. Morgan Stanley raised the price target on November 8 changing the forecast from $45.00 to $49.00 and issued a “Equal Weight” recommendation. Equity analyst BMO Capital Markets raised the price target on November 8 changing the price objective from $64.00 to $65.00 with a “Outperform” recommendation.
On October 17 Needham & Company LLC kept the stock rating at “Buy” targeting a price of $64.00. October 13 investment analysts at Stifel Nicolaus maintained a stock rating of “Hold” with a current price target of $50.00.
On October 6 Goldman Sachs Group, Inc. (The) made no change to the company rating of “Sell” projecting a price of $30.00. October 2 investment analysts at BMO Capital Markets made no change to the stock rating of “Outperform” with a current price target of $69.00.